Tüsüz Önata E, Özdemir Ö. Fecal microbiota transplantation in allergic diseases. World J Methodol 2025; 15(2): 101430 [DOI: 10.5662/wjm.v15.i2.101430]
Corresponding Author of This Article
Öner Özdemir, MD, Professor, Division of Pediatric Allergy and Immunology, Medical Faculty, Sakarya University, Adnan Menderes cad, Adapazarı 54100, Sakarya, Türkiye. ozdemir_oner@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Methodol. Jun 20, 2025; 15(2): 101430 Published online Jun 20, 2025. doi: 10.5662/wjm.v15.i2.101430
Fecal microbiota transplantation in allergic diseases
Ece Tüsüz Önata, Öner Özdemir
Ece Tüsüz Önata, Öner Özdemir, Division of Pediatric Allergy and Immunology, Medical Faculty, Sakarya University, Adapazarı 54100, Sakarya, Türkiye
Author contributions: Tüsüz Önata E and Özdemir Ö performed the research, wrote the article. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Öner Özdemir, MD, Professor, Division of Pediatric Allergy and Immunology, Medical Faculty, Sakarya University, Adnan Menderes cad, Adapazarı 54100, Sakarya, Türkiye. ozdemir_oner@hotmail.com
Received: September 13, 2024 Revised: October 17, 2024 Accepted: November 1, 2024 Published online: June 20, 2025 Processing time: 74 Days and 15.1 Hours
Abstract
Microorganisms such as bacteria, fungi, viruses, parasites living in the human intestine constitute the human intestinal microbiota. Dysbiosis refers to compositional and quantitative changes that negatively affect healthy gut microbiota. In recent years, with the demonstration that many diseases are associated with dysbiosis, treatment strategies targeting the correction of dysbiosis in the treatment of these diseases have begun to be investigated. Faecal microbiota transplantation (FMT) is the process of transferring faeces from a healthy donor to another recipient in order to restore the gut microbiota and provide a therapeutic benefit. FMT studies have gained popularity after probiotic, prebiotic, symbiotic studies in the treatment of dysbiosis and related diseases. FMT has emerged as a potential new therapy in the treatment of allergic diseases as it is associated with the maintenance of intestinal microbiota and immunological balance (T helper 1/T helper 2 cells) and thus suppression of allergic responses. In this article, the definition, application, safety and use of FMT in allergic diseases will be discussed with current data.
Core Tip: Fecal microbiota transplantation (FMT) studies have gained popularity after probiotic, prebiotic, symbiotic studies in the treatment of dysbiosis and related diseases. FMT is the process of transferring faeces from a healthy donor to another recipient in order to restore the gut microbiota and provide a therapeutic benefit.
